BIO’s Industry Analysis Team has reviewed and annotated pipeline data from BioCentury and Biomedtracker to create a granular, interactive view of the Covid-19 pipeline. The team has investigated each drug as to original inventor (company/country), mechanism of action and strategic approach, as well as de-duplicated multiple company and university programs for the same active ingredient (for example, hydroxychloroquine is counted only once).
The data below shows two key things:
- Biopharma companies - particularly small biotech companies - are undertaking a monumental campaign to combat, and hopefully eradicate, Covid-19.
- Innovation is being led by U.S.-based companies.
This data will be updated weekly on Monday.